Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.
News|Articles|October 1, 2025
6 Allergy Headlines You Missed in September 2025
Author(s)Chelsie Derman
Fact checked by: Victoria Johnson
This month in review features the latest breakthroughs in allergy treatments, including innovative therapies for cat and peanut allergies.
Advertisement
Advertisement
As September 2025 wraps up, advances in clinical research are offering fresh insights into
Related to this article
The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.
Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Two monoclonal antibodies isolated from malaria-exposed donors blocked patient IgE from binding key alpha-gal allergens and suppressed basophil activation.
What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.
Advertisement
Advertisement